|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0030705,
umls-concept:C0178602,
umls-concept:C0184511,
umls-concept:C0332307,
umls-concept:C0871261,
umls-concept:C1452601,
umls-concept:C1570906,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2587213,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-10-12
|
|
pubmed:abstractText |
A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4). This study was designed to establish a dose of the DPP-4-inhibitor vildagliptin (LAF237) that was effective in reducing HbA1c levels and was safe and well tolerated in patients with type 2 diabetes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adamantane,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Deaminase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/DPP4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl Peptidase 4,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines,
http://linkedlifedata.com/resource/pubmed/chemical/vildagliptin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1462-8902
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
692-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16219012-Adamantane,
pubmed-meshheading:16219012-Adenosine Deaminase Inhibitors,
pubmed-meshheading:16219012-Adult,
pubmed-meshheading:16219012-Aged,
pubmed-meshheading:16219012-Blood Glucose,
pubmed-meshheading:16219012-Diabetes Mellitus, Type 2,
pubmed-meshheading:16219012-Dipeptidyl Peptidase 4,
pubmed-meshheading:16219012-Dose-Response Relationship, Drug,
pubmed-meshheading:16219012-Double-Blind Method,
pubmed-meshheading:16219012-Drug Administration Schedule,
pubmed-meshheading:16219012-Female,
pubmed-meshheading:16219012-Glycoproteins,
pubmed-meshheading:16219012-Hemoglobin A, Glycosylated,
pubmed-meshheading:16219012-Humans,
pubmed-meshheading:16219012-Hypoglycemic Agents,
pubmed-meshheading:16219012-Insulin,
pubmed-meshheading:16219012-Male,
pubmed-meshheading:16219012-Middle Aged,
pubmed-meshheading:16219012-Nitriles,
pubmed-meshheading:16219012-Postprandial Period,
pubmed-meshheading:16219012-Pyrrolidines
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
|
|
pubmed:affiliation |
Novartis Pharma, Basel, Switzerland. smiliana.ristic@novartis.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
